Joseph Dolina | Senior Scientist

Joseph Dolina, Senior Scientist, Pfizer

Dr. Dolina joined Pfizer in 2019 focused on developing first-in-class CD8+ T cell-mediated cancer immunotherapies. He holds dual B.S. degrees in Biology and Chemistry from The College of New Jersey, an M.S. in Biomedical Sciences from the University of Medicine and Dentistry of New Jersey, and a Ph.D. in Microbiology from the University of Virginia. His postdoctoral research was conducted at the world-renowned La Jolla Institute for Immunology. With over 16 years of experience investigating diseases including acute and chronic viral infection, bacterial infection, and cancer, Dr. Dolina’s expertise and work span regulatory and helper CD4+ T cell biology and how these cells influence cytotoxic CD8+ T cell function. His findings have important implications on the fundamental mechanisms governing natural immune tolerance, T cell plasticity in relation to inflammation and priming, and the development of personalized neoantigen vaccination for cancer.


Day 2 - November 29 @ 15:00

Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

last published: 02/Jan/24 12:15 GMT

back to speakers